Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors

Oncotarget

Volumn 5, Issue 12, 2014, Pages 4071-4086

  Yeh, Chun Nan ^a   Yen, Chueh Chuan ^b,c   Chen, Yen Yang ^d   Cheng, Chi Tung ^a   Huang, Shih Chiang ^a   Chang, Ting Wei ^b   Yao, Fang Yi ^b   Lin, Yung Chan ^b   Wen, Yao Shan ^b   Chiang, Kun Chun ^a   Chen, Jen Shi ^a   Yeh, Ta Sen ^a   Tzeng, Cheng Hwai ^b,c   Chao, Ta Chung ^b,c   Fletcher, Jonathan A ^e  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aurora kinase A; Gastrointestinal stromal tumor; Imatinib mesylate; MLN8237

Indexed keywords

ALISERTIB; AURORA A KINASE; IMATINIB; PROTEIN P21; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; M PHASE CELL CYCLE CHECKPOINT; MAJOR CLINICAL STUDY; MALE; METASTASIS; MITOSIS INHIBITION; OVERALL SURVIVAL; PHYSICAL PERFORMANCE; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; RECURRENT DISEASE; TUMOR CELL CULTURE; TUMOR VOLUME; CELL AGING; DISEASE FREE SURVIVAL; GASTROINTESTINAL STROMAL TUMORS; PROGNOSIS; TREATMENT OUTCOME;

AURORA KINASE A; CELL AGING; DISEASE-FREE SURVIVAL; GASTROINTESTINAL STROMAL TUMORS; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84905106853     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1705     Document Type: Article

References (49)

1. Tran T, Davila JA and El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005; 100(1): 162-168.
2. Miettinen M and Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006; 130(10): 1466-1478.
3. Reith JD, Goldblum JR, Lyles RH and Weiss SW. Extra gastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000; 13(5): 577-585.
4. Kindblom LG, Remotti HE, Aldenborg F and Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998; 152(5): 1259-1269.
5. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad TG, Matsuzawa Y, Kanakura Y, Shinomura Y and Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279(5350): 577-580.
6. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD and Fletcher JA. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299(5607): 708-710.
7. Blanke CD, Demetri GD, von MM, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z and Joensuu H. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26(4): 620-625.
8. Yeh CN, Chen YY, Tseng JH, Chen JS, Chen TW, Tsai CY, Cheng CT, Jan YY and Chen MF. Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan. Transl Oncol. 2011; 4(6): 328-335.
9. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von MM, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ and Fletcher JA. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006; 24(29): 4764-4774.
10. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010; 28(7): 1247-1253.
11. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM and Demetri GD. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinibin imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008; 26(33): 5352-5359.
12. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X and Baum CM, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368(9544): 1329-1338.
13. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von MM, Joensuu H, Badalamenti G, Blackstein M, Le CA, Schoffski P, Maki RG and Bauer S, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863): 295-302.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH and Weiss SW. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002; 33(5): 459-465.
15. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39(10): 1411-1419.
16. Miettinen M and Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23(2): 70-83.
17. Yen CC, Yeh CN, Cheng CT, Jung SM, Huang SC, Chang TW, Jan YY, Tzeng CH, Chao TC, Chen YY, Yang CY, Ho CL and Fletcher JA. Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker. Ann Surg Oncol. 2012; 19(11): 3491-3499.
18. Lagarde P, Perot G, Kauffmann A, Brulard C, Dapremont V, Hostein I, Neuville A, Wozniak A, Sciot R, Schoffski P, Aurias A, Coindre JM, biec-Rychter M and Chibon F. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res. 2012; 18(3): 826-838.
19. Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, Lucchesi C, de RA, Kauffmann A, Bui B, Terrier P, Bonvalot S, Le CA, Vince-Ranchere D, Blay JY and Collin F, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010; 16(7): 781-787.
20. Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M and Carrasco RD, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010; 115(25): 5202-5213.
21. Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ and Carew JS. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med. 2011; 15(10): 2057-2070.
22. Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Persky AM, Miller TP and Mahadevan D. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol. 2011; 81(7): 881-890.
23. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr and Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008; 14(6): 1639-1648.
24. Chou TC and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; (22):27-55.
25. Ewald JA, Desotelle JA, Wilding G and Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst. 2010; 102(20): 1536-1546.
26. Zhu Y, Xu L, Zhang J, Hu X, Liu Y, Yin H, Lv T, Zhang H, Liu L, An H, Liu H, Xu J and Lin Z. Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinomacells. Cancer Sci. 2013; 104(8): 1052-1061.
27. Shan W, Akinfenwa PY, Savannah KB, Kolomeyevskaya N, Laucirica R, Thomas DG, Odunsi K, Creighton CJ, Lev DC and Anderson ML. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clin Cancer Res. 2012; 18(12): 3352-3365.
28. Marumoto T, Zhang D and Saya H. Aurora-A-a guardian of poles. Nat Rev Cancer. 2005; 5(1): 42-50.
29. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H and Sen S. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res. 2003; 9(3): 991-997.
30. Wong FH, Huang CY, Su LJ, Wu YC, Lin YS, Hsia JY, Tsai HT, Lee SA, Lin CH, Tzeng CH, Chen PM, Chen YJ, Liang SC, Lai JM and Yen CC. Combination of microarray profiling and protein-protein interaction databases delineates the minimal discriminators as a metastasisnetwork for esophageal squamous cell carcinoma. Int J Oncol. 2009; 34(1): 117-128.
31. Jeng YM, Peng SY, Lin CY and Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res. 2004; 10(6): 2065-2071.
32. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W and Czerniak B. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst. 2002; 94(17): 1320-1329.
33. Vader G and Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta. 2008; 1786(1): 60-72.
34. Keen N and Taylor S. Aurora-kinase inhibitors as anticanceragents. Nat Rev Cancer. 2004; 4(12): 927-936.
35. Sehdev V, Katsha A, Ecsedy J, Zaika A, Belkhiri A and El-Rifai W. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas. Cancer. 2013; 119(4): 904-914.
36. Dees EC, Cohen RB, von MM, Stinchcombe TE, Liu H, Venkatakrishnan K, Manfredi M, Fingert H, Burris HAIII and Infante JR. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res. 2012; 18(17): 4775-4784.
37. Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Rosello S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Manos L, Perez-Fidalgo JA, Fingert H and Baselga J, et al. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012; 18(17): 4764-4774.
38. Cazzalini O, Scovassi AI, Savio M, Stivala LA and Prosperi E. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat Res. 2010; 704 (1-3):12-20.
39. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY). 2012; 4(3): 159-165.
40. Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Caponigro G, Schnepp RW, Wood AC and Pawel B, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013; 1922:6173-6182.
41. Leontieva OV, Demidenko ZN and Blagosklonny MV. MEK drives cyclin D1 hyperelevation during geroconversion. Cell Death Differ. 2013; 20(9): 1241-1249.
42. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228-247.
43. Bauer S, Yu LK, Demetri GD and Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006; 66(18): 9153-9161.
44. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA and Demetri GD. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001; 20(36): 5054-5058.
45. Pozarowski P and Darzynkiewicz Z. Analysis of cell cycle by flow cytometry. Methods Mol Biol. 2004; 281:301-311.
46. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63.
47. Schmit TL, Nihal M, Ndiaye M, Setaluri V, Spiegelman VS and Ahmad N. Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis. Cancer Res. 2012; 72(15): 3864-3872.
48. Pozarowski P, Grabarek J and Darzynkiewicz Z. Flow cytometry of apoptosis. Curr Protoc Cell Biol. 2004; Chapter 18 Unit.
49. Muller-Tidow C, Metzger R, Kugler K, Diederichs S, Idos G, Thomas M, Dockhorn-Dworniczak B, Schneider PM, Koeffler HP, Berdel WE and Serve H. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res. 2001; 61(2): 647-653.